WO2016150349A1 - 一种pci-32765晶型a的制备方法 - Google Patents

一种pci-32765晶型a的制备方法 Download PDF

Info

Publication number
WO2016150349A1
WO2016150349A1 PCT/CN2016/076779 CN2016076779W WO2016150349A1 WO 2016150349 A1 WO2016150349 A1 WO 2016150349A1 CN 2016076779 W CN2016076779 W CN 2016076779W WO 2016150349 A1 WO2016150349 A1 WO 2016150349A1
Authority
WO
WIPO (PCT)
Prior art keywords
pci
preparation
crystal form
crystal
solvent
Prior art date
Application number
PCT/CN2016/076779
Other languages
English (en)
French (fr)
Inventor
陈敏华
张炎锋
张良
纪书林
Original Assignee
苏州晶云药物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州晶云药物科技有限公司 filed Critical 苏州晶云药物科技有限公司
Priority to AU2016236578A priority Critical patent/AU2016236578B2/en
Priority to CA2980418A priority patent/CA2980418C/en
Priority to JP2017567523A priority patent/JP6657269B2/ja
Priority to EP16767726.9A priority patent/EP3272753B1/en
Priority to MX2017011990A priority patent/MX2017011990A/es
Priority to US15/559,777 priority patent/US10138239B2/en
Publication of WO2016150349A1 publication Critical patent/WO2016150349A1/zh
Priority to IL254530A priority patent/IL254530A0/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Definitions

  • the invention relates to the field of medical chemistry, in particular to a preparation method of PCI-32765 crystal form A.
  • PCI-32765 (a compound of formula I) was developed by the US biopharmaceutical company Pharmacyclics, and on November 13, 2013, the US Food and Drug Administration (FDA) approved a single therapeutic drug for mantle cell lymphoma, also known as Ibrutinib.
  • BTK Bruton's tyrosine kinase
  • Patent CN104327085A discloses a pharmaceutically useful new crystalline form of PCI-32765, designated Form A, which also discloses a Form A preparation process. This method is a small-scale preparation method, and so far, a stable and reliable method for preparing crystal form A by amplification has not been seen.
  • a method for preparing PCI-32765 crystal form A comprising the following steps:
  • step 1) The solution in the step 1) is added dropwise to the anti-solvent, and after the addition is completed, the solution is stirred at a temperature of 0 to 20 ° C, and the seed crystal of PCI-32765 crystal form A is added, or the step 1) The solution is added dropwise to a suspension containing PCI-32765 crystal form A seed crystal at a temperature of 0 to 20 ° C;
  • step 2) controlling the step 2) to obtain a solution system which is continuously stirred and matured until the crystal transformation is completed to obtain a crystal slurry;
  • positive solvent may be a single solvent or a mixed solvent, and in the present invention means a single solvent or a mixed solvent which is soluble in PCI-32765 free base.
  • the positive solvent is methanol or a mixed solvent containing methanol.
  • the mixed solvent is methanol and dimethyl sulfoxide in a volume ratio of 1:0.8 to 1.2.
  • the PCI-32765 free base solution is formulated at 10 to 50 °C.
  • anti-solvent has its ordinary meaning in the art, and in the present invention means a solvent in which PCI-32765 Form A is added to a solvent to cause precipitation.
  • the anti-solvent is pure water.
  • the mass ratio of the seed crystal of PCI-32765 crystal form A described in step 2) to the mass ratio of PCI-32765 free base described in step 1) is from 0.01 to 0.1:1.
  • the ratio of the feed volume of the positive solvent to the mass ratio of the PCI-32765 free base is 10 to 40 mL/g.
  • the feed volume of the anti-solvent described in step 2) and the charge-to-mass ratio of PCI-32765 free base described in step 1) are from 30 to 80 mL/g.
  • step 2) the solution in the step 1) is added dropwise to the anti-solvent or the suspension at a rate of 1 to 30 mL/min.
  • the temperature conditions described in step 2) are from 0 to 10 °C.
  • the temperature condition described in step 2) is 0 to 5 °C.
  • the temperature of the ripening described in step 3) is from 0 to 40 °C.
  • the temperature of the ripening described in the step 3) is 0 to 30 °C.
  • the ripening temperature is 0 to 20 °C.
  • the ripening time described in step 3) is from 5 to 48 hours.
  • the ripening time described in step 3) is 5 to 24 hours.
  • the ripening time described in step 3 is from 14 to 20 hours.
  • the specific method of the step 3) is: controlling the solution system obtained in the step 2) to continue stirring, and then curing at a constant temperature of 0 to 5 ° C for 15 to 24 hours; or, the solution system obtained in the step 2) is 0 to 0. After maintaining at 5 ° C for 1 to 3 hours, the temperature is raised to 10 to 20 ° C, and maintained at 10 to 20 ° C for 10 to 15 hours to obtain a crystal slurry.
  • the washing solvent used in step 4) is pure water.
  • the drying conditions in step 4) are controlled as follows: The washed sample is placed in a vacuum oven at 30-50 ° C and dried to a constant weight of the sample.
  • the preparation method of the crystal form A provided by the invention has the characteristics of simple process operation, stable and controllable process, high yield, environmental friendliness and good impurity removal ability, and the prepared crystal form A can be stably stored, wettability and solubility are consistent. Medicinal requirements.
  • the preparation method of the crystal form A provided by the invention breaks through the bottleneck of the prior art which is difficult to scale production, and solves the problem of industrial production.
  • Figure 1 is an X-ray powder diffraction pattern of PCI-32765 Form A
  • Figure 3 is a thermogravimetric analysis diagram of PCI-32765 crystal form A
  • the preparation method of the crystal form A provided by the invention has the advantages of simple process operation, stable and controllable process, high yield, environmental friendliness, good impurity removal ability, and the prepared crystal form A can be stably stored, hygroscopicity and solubility are in accordance with the medicinal use. Claim.
  • the starting material used in the present invention is a crude product of PCI-32765 free base, which is obtained by commercially available means, and the test method is usually carried out according to conventional conditions or conditions recommended by the manufacturer.
  • the room temperature is usually 25 °C.
  • the X-ray powder diffraction pattern of the present invention was collected on a Panalytical Empyrean X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of the differential scanning calorimetry (DSC) described in the present invention are as follows:
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q5000.
  • the method parameters of the thermogravimetric analysis (TGA) described in the present invention are as follows:
  • PCI-32765 Form A Three batches of PCI-32765 Form A were produced as follows.
  • step 3 The solution of PCI-32765 free base in the step 1) was added dropwise to the suspension in the step 2) at a uniform rate for about 1 hour. After the completion of the dropwise addition, the mixture was maintained at 0 ° C for 2 hours, and then the crystal system was heated to 20 ° C in 4 hours. After the aging for 14 hours, a crystal slurry was obtained, and the crystal form of the product was sampled by XRPD and completely converted into Form A.
  • the first batch described above having a scale of 35 g, obtained a solid product, weighed, had a mass of 35.4 g, a yield of 91.1%, and a purity of 100.0%.
  • the product is tested by XRPD and is the crystal form A of PCI-32765.
  • the second batch process was the same as the first batch, the scale was 50g, and the obtained solid product was weighed, the mass was 50.75g, the yield was 91.5%, and the purity was 99.8%.
  • the product is tested by XRPD and is the crystal form A of PCI-32765.
  • the third batch process was the same as the first batch, and the scale was 75 g of the obtained solid product, weighed, the mass was 75.2 g, the yield was 90.3%, and the purity was 99.7%.
  • the product is tested by XRPD, which is PCI-32765. Form A.
  • the X-ray powder diffraction data of the crystal form obtained in this example is shown in Table 1. Its XRPD diagram is shown in Figure 1, its DSC diagram is shown in Figure 2, and its TGA diagram is shown in Figure 3.
  • PCI-32765 Form A Three batches of PCI-32765 Form A were produced as follows.
  • the first batch described above had a scale of 50 g, and the obtained solid product was weighed, the mass was 48.4 g, the yield was 86.8%, and the purity was 99.9%.
  • the product is tested by XRPD and is the crystal form A of PCI-32765.
  • the second batch process was the same as the first batch, the scale was 5g, the obtained solid product was weighed, the mass was 4.8g, the yield was 86.0%, and the purity was 100.0%.
  • the product is tested by XRPD and is the crystal form A of PCI-32765.
  • the third batch process was the same as the first batch, the scale was 5g, the obtained solid product was weighed, the mass was 4.4g, the yield was 78.0%, and the purity was 100.0%.
  • the product is tested by XRPD and is the crystal form A of PCI-32765.
  • step 3 The solution of PCI-32765 free base in the step 1) was added dropwise to the suspension in the step 2) at a uniform rate for about 1 hour. After the completion of the dropwise addition, the mixture was maintained at 2 ° C for 1 hour, and then the crystal system was heated to 40 ° C in 1 hour. After aging for 16 hours, a crystal slurry was obtained, and the crystal form of the product was detected by XRPD and completely converted into crystal form A.
  • the solid product obtained in the batch was weighed, the mass was 10.1 g, the yield was 91.1%, and the purity was 99.53%. It is detected by XRPD and is the crystal form A of PCI-32765.
  • step 3 The solution of PCI-32765 free base in the step 1) was added dropwise to the suspension in the step 2) at a uniform rate for about 1 hour. After the completion of the dropwise addition, the mixture was maintained at 5 ° C for 1 hour, and then the crystal system was heated to 40 ° C in 1 hour. After the aging for 16 hours, the crystal slurry was sampled and the crystal form of the product was detected by XRPD, and the crystal form was completely converted.
  • the solid product obtained in this batch was weighed and had a mass of 9.5 g, a yield of 94.9%, and a purity of 99.90%. It is detected by XRPD and is the crystal form A of PCI-32765.
  • PCI-32765 Form A Two batches of PCI-32765 Form A were produced as follows.
  • step 3 The solution of PCI-32765 free base in step 1) was added dropwise to the suspension in step 2) at a uniform rate for about 10 minutes. After the completion of the dropwise addition, the crystal slurry was obtained by maintaining at 0 ° C for 20 hours, and the sample was sampled by XRPD to detect the crystal form of the product, which was completely converted into the crystal form A.
  • the scale is 1g
  • the obtained solid product weighed
  • the mass is 0.89g
  • the yield is 79.0%
  • purity is 100.0%. It is detected by XRPD and is the crystal form A of PCI-32765.
  • the second batch process was the same as the first batch, the scale was 0.3 g, and the obtained solid product was weighed, the mass was 0.27 g, the yield was 80.0%, and the purity was 100.0%.
  • the product is tested by XRPD and is the crystal form A of PCI-32765.

Abstract

一种PCI-32765晶型A的制备方法，所述制备方法包括如下步骤：1)将PCI-32765的游离碱固体溶解于正溶剂中；2)将步骤1)中的溶液滴加到反溶剂中，滴加完毕后搅拌，并加入PCI-32765晶型A的晶种，或将步骤1)中的溶液滴加到含PCI-32765晶型A晶种的悬浊液中；3)控制步骤2)所得的溶液体系持续搅拌，熟化，获得晶浆；4)晶浆经过滤，洗涤，干燥后得到PCI-32765晶型A的粉末。该制备方法具有工艺操作简单、过程稳定可控、收率高、环境友好、除杂能力好、适合工业化生产的特点，且制备得到的晶型A能稳定储存，引湿性，溶解度符合药用要求。

Description

一种PCI-32765晶型A的制备方法 技术领域
本发明涉及医药化学领域，特别是涉及PCI-32765晶型A的制备方法。
背景技术
PCI-32765(式I所示的化合物)是由美国生物制药公司Pharmacyclics开发，2013年11月13日美国食品药品管理局(FDA)已批准作为套细胞淋巴癌的单个治疗药物，又名Ibrutinib。Ibrutinib制成的靶向制剂，可选择性地抑制布鲁顿酪氨酸激酶(BTK)，该酶是至少三种关键B-细胞生存机制的重要介质。布鲁顿酪氨酸激酶的这种多重作用可以使其指挥B-细胞恶性肿瘤进行入淋巴组织，使肿瘤细胞能够接触必要的微环境而得以生存。美国食品药品管理局(FDA)已授予该化合物(Ibrutinib)“突破性”地位用于治疗两种B-细胞恶性肿瘤。该化合物的化学名称为1-[(3R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3，4-D]嘧啶-1-基]-1-哌啶基]-2-丙烯-1-酮，结构如下所示：
Figure PCTCN2016076779-appb-000001
专利CN104327085A公开了PCI-32765的一种药学上可用的新晶型，命名为晶型A，该专利还公开了晶型A制备方法。该方法为小试制备方法，迄今，尚未见稳定且可靠的放大制备晶型A的方法。
为解决现有技术存在的难题，提供适合工业化生产的PCI-32765晶型A的制备工艺十分必要。
发明内容
本发明的目的是提供一种PCI-32765晶型A的制备方法。与现有工艺相比，本发明的制备工艺过程可控，能稳定可靠地放大，适合工业化生产。
为解决上述技术问题，本发明采用如下技术方案：
一种PCI-32765晶型A的制备方法，包括以下步骤：
1)PCI-32765游离碱溶液的配制：将PCI-32765的游离碱固体溶解于正溶剂中；
2)将步骤1)中的溶液滴加到反溶剂中，滴加完毕后在0～20℃的温度条件下搅拌，并加入PCI-32765晶型A的晶种，或将步骤1)中的溶液在0～20℃的温度条件下滴加到含PCI-32765晶型A晶种的悬浊液中；
3)控制步骤2)所得的溶液体系持续搅拌熟化至转晶完全，获得晶浆；
4)步骤3)中所述晶浆，经过滤，洗涤，干燥后，得到PCI-32765晶型A的粉末。
术语“正溶剂”可以是单一溶剂或混合溶剂，本发明中是指对PCI-32765游离碱溶解性好的单一溶剂或混合溶剂。
优选地，所述正溶剂为甲醇或含甲醇的混合溶剂。
根据本发明，所述的混合溶剂为体积比为1∶0.8～1.2的甲醇和二甲亚砜。
优选地，步骤1)中，在10～50℃下配制所述的PCI-32765游离碱溶液。
术语“反溶剂”具有在本领域中的普通含义，本发明中是指PCI-32765晶型A加入到溶剂中导致沉淀析出的溶剂。
优选地，所述反溶剂为纯水。
优选地，步骤2)中所述的PCI-32765晶型A的晶种的投料质量与步骤1)中所述的PCI-32765游离碱投料质量比为0.01～0.1∶1。
优选地，步骤1)中，所述的正溶剂的投料体积与所述的PCI-32765游离碱的投料质量比为10～40mL/g。
优选地，步骤2)中所述的反溶剂的投料体积与步骤1)中所述的PCI-32765游离碱的投料质量比为30～80mL/g。
优选地，步骤2)中，所述的步骤1)中的溶液滴加到所述的反溶剂或所述的悬浊液中的速度为1～30mL/min。
优选地，步骤2)中所述的温度条件为0～10℃。
进一步优选地，步骤2)中所述的温度条件为0～5℃。
优选地，步骤3)中所述的熟化的温度为0～40℃。
进一步优选地，步骤3)中所述的熟化的温度为0～30℃。
更为优选地，所述的熟化的温度为0～20℃。
优选地，步骤3)中所述的熟化的时间为5～48小时。
进一步优选地，步骤3)中所述的熟化的时间为5～24小时。
更为优选地，步骤3)中所述的熟化的时间为14～20小时。
根据本发明，步骤3)的具体方法为：控制步骤2)所得的溶液体系持续搅拌，然后在0～5℃下恒温熟化15～24小时；或者，将步骤2)所得的溶液体系在0～5℃维持1～3小时，然后升温至10～20℃，在10～20℃下维持10～15小时，获得晶浆。
优选地，步骤4)中所用的洗涤溶剂为纯水。
优选地，步骤4)中的干燥条件的控制如下：将洗涤过的样品放置于30～50℃的真空干燥箱中干燥至样品恒重。
本发明的有益效果：
本发明提供的晶型A的制备方法具有工艺操作简单、过程稳定可控、收率高、环境友好、除杂能力好的特点，且制备得到的晶型A能稳定储存，引湿性，溶解度符合药用要求。
本发明提供的晶型A的制备方法，突破了现有技术难以规模化生产的瓶颈，解决了工业化生产的难题。
附图说明
图1为PCI-32765晶型A的X射线粉末衍射图；
图2为PCI-32765晶型A的差示扫描量热图；
图3为PCI-32765晶型A的热重分析图；
图4为对比例3制得的晶型的X射线粉末衍射图。
具体实施方式
本发明人通过研究开发，优化工艺，找到了一种可用于工业生产的晶型A的制备方法，突破了现有技术难以规模化生产的瓶颈，解决了工业化生产的难题。
本发明提供的晶型A的制备方法具有工艺操作简单、过程稳定可控、收率高、环境友好、除杂能力好，且制备得到的晶型A能稳定储存，引湿性，溶解度符合药用要求。
以下将通过具体实施例进一步阐述本发明，但并不用于限制本发明的保护范围。本领域技术人员可在权利要求范围内对制备方法和使用仪器作出改进， 这些改进也应视为本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。
本发明中所用原料为PCI-32765游离碱的粗品，由市售购买的方式获得，所述的试验方法通常按照常规条件或制造厂商建议的条件实施。室温通常为25℃。
本发明中所用到的缩写的解释如下：
XRPD：X射线粉末衍射
DSC：差示扫描量热分析
TGA：热重分析
本发明所述的X射线粉末衍射图在Panalytical Empyrean X射线粉末衍射仪上采集。本发明所述的X射线粉末衍射的方法参数如下：
X射线反射参数：Cu，Kα
Kα1
Figure PCTCN2016076779-appb-000002
：1.540598；Kα2
Figure PCTCN2016076779-appb-000003
：1.544426
Kα2/Kα1强度比例：0.50
电压：45仟伏特(kV)
电流：40毫安培(mA)
扫描范围：自3.0至40.0度
本发明所述的差示扫描量热分析(DSC)图在TA Q2000上采集。本发明所述的差示扫描量热分析(DSC)的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
本发明所述的热重分析(TGA)图在TA Q5000上采集。本发明所述的热重分析(TGA)的方法参数如下：
扫描速率：10℃/min
保护气体：氮气
实施例1
PCI-32765晶型A的制备方法：按下述方法生产三批次的PCI-32765晶型A。
1)称取35.0g PCI-32765游离碱固体，在室温条件下加入1260mL甲醇，预过滤后将澄清溶液在25～40℃条件下密封保存待用。
2)取1000mL纯水加入到10L的夹套结晶釜内，开启搅拌和降温程序，使体系温度控制到0℃左右。然后称取3.5g PCI-32765晶型A的晶种，加入结晶釜，随后向结晶釜中继续添加纯水至2520mL，搅拌形成含有晶型A晶种的悬浊液。
3)将步骤1)中的PCI-32765游离碱的溶液在1小时左右匀速地滴加至步骤2)中的悬浊液中。滴加完毕后，在0℃维持2小时，然后在4小时内将结晶体系升温至20℃，熟化14小时后获得晶浆，取样通过XRPD检测产品晶型，已完全转变为晶型A。
4)过滤步骤3)所得的晶浆，得到湿滤饼，用70mL纯水淋洗滤饼，然后在45℃的真空干燥箱中干燥滤饼约20小时至样品恒重。
上述第一批次，规模为35g，所得固体产品，称重，质量为35.4g，收率为91.1％，纯度为100.0％。产品经XRPD检测，即为PCI-32765的晶型A。
第二批次工艺方法同第一批次，规模为50g，所得固体产品，称重，质量为50.75g，收率为91.5％，纯度为99.8％。产品经XRPD检测，即为PCI-32765的晶型A。
第三批次工艺方法同第一批次，规模为75g所得固体产品，称重，质量为75.2g，收率为90.3％，纯度为99.7％。产品经XRPD检测，即为PCI-32765 的晶型A。
本实施例得到的晶型的X射线粉末衍射数据如表1所示。其XRPD图如图1，其DSC图如图2，其TGA图如图3。
表1
2theta d间隔 相对强度％
5.23 16.91 100.00
11.26 7.86 4.69
16.22 5.47 4.86
16.44 5.39 2.12
17.65 5.03 12.28
18.09 4.91 4.76
18.86 4.71 7.03
19.28 4.60 11.48
20.75 4.28 6.76
22.07 4.03 11.15
22.46 3.96 8.33
23.00 3.87 4.29
25.90 3.44 3.16
实施例2
PCI-32765晶型A的制备方法：按下述方法生产三批次的PCI-32765晶型A。
1)称取50.1g PCI-32765游离碱固体，在室温条件下加入1800mL甲醇，预过滤后将澄清溶液在25～40℃下密封保存待用。
2)取1000mL纯水加入到10L的夹套结晶釜内，开启搅拌和温程序，使体系温度控制到0℃左右。然后称取5.0g PCI-32765晶型A的晶种，加入结晶釜，随后向结晶釜中继续添加纯水至2600mL，搅拌形成含有晶型A晶种的悬浊液。
3)将步骤1)中的PCI-32765游离碱的溶液在1小时左右匀速地滴加至步骤2)中的悬浊液中。滴加完毕后，在0℃维持20小时获得晶浆，取样通过XRPD检测产品晶型，已完全转变为晶型A。
4)过滤步骤3)所得的晶浆，得到湿滤饼，用100mL纯水淋洗滤饼，然后在45℃的真空干燥箱中干燥滤饼约20小时至样品恒重。
上述第一批次，规模为50g，所得固体产品，称重，质量为48.4g，收率为86.8％，纯度为99.9％。产品经XRPD检测，即为PCI-32765的晶型A。
第二批次工艺方法同第一批次，规模为5g，所得固体产品，称重，质量为4.8g，收率为86.0％，纯度为100.0％。产品经XRPD检测，即为PCI-32765的晶型A。
第三批次工艺方法同第一批次，规模为5g，所得固体产品，称重，质量为4.4g，收率为78.0％，纯度为100.0％。产品经XRPD检测，即为PCI-32765的晶型A。
本实施例得到的晶型的X射线粉末衍射数据如表2所示。
表2
2theta d间隔 相对强度％
5.18 17.06 19.84
11.25 7.87 12.41
16.19 5.47 35.00
16.43 5.40 16.26
17.34 5.11 16.63
17.63 5.03 19.00
18.06 4.91 30.56
18.85 4.71 28.54
19.28 4.60 62.29
20.73 4.28 26.85
22.06 4.03 100.00
22.43 3.96 21.09
22.99 3.87 40.74
23.87 3.73 11.47
25.89 3.44 11.11
实施例3
PCI-32765晶型A的制备方法：
1)称取10.0g PCI-32765游离碱固体，在50℃条件下加入160mL甲醇，预过滤后将澄清溶液在50℃条件下密封保存待用。
2)称取0.99g PCI-32765晶型A的晶种，加入320mL纯水制成悬浊液，并将体系温度控制到2℃左右。
3)将步骤1)中的PCI-32765游离碱的溶液在1小时左右匀速地滴加至步骤2)中的悬浊液中。滴加完毕后，在2℃维持1小时，然后在1小时内将结晶体系升温至40℃，熟化16小时后获得晶浆，取样通过XRPD检测产品晶型，已完全转变为晶型A。
4)过滤步骤3)所得的晶浆，得到湿滤饼，用20mL纯水淋洗滤饼，然后在50℃的真空干燥箱中干燥滤饼约20小时至样品恒重。
该批次所得固体产品，称重，质量为10.1g，收率为91.1％，纯度为99.53％。经XRPD检测，即为PCI-32765的晶型A。
本实施例得到的晶型的X射线粉末衍射数据如表3所示。
表3
2theta d间隔 相对强度％
5.20 17.01 100.00
8.48 10.42 1.62
9.60 9.21 2.81
10.40 8.50 1.84
11.23 7.88 8.49
13.03 6.80 1.41
13.19 6.71 1.26
14.88 5.95 0.28
15.33 5.78 0.54
16.20 5.47 10.48
16.41 5.40 5.36
16.99 5.22 1.59
17.34 5.12 4.44
17.63 5.03 19.25
18.05 4.91 8.87
18.85 4.71 13.09
19.27 4.61 19.97
20.01 4.44 0.91
20.53 4.33 3.09
20.75 4.28 11.45
22.07 4.03 22.16
22.45 3.96 13.29
22.98 3.87 9.27
23.88 3.73 2.60
24.52 3.63 1.47
25.04 3.56 2.74
25.89 3.44 5.38
26.32 3.39 1.07
26.57 3.35 0.76
27.77 3.21 1.15
27.95 3.19 1.99
28.72 3.11 1.44
28.94 3.09 1.82
29.51 3.03 0.35
实施例4
PCI-32765晶型A的制备方法：
1)称取9.99g PCI-32765游离碱固体，在50℃条件下加入160mL甲醇，预过滤后将澄清溶液在50℃条件下密封保存待用。
2)称取101.2mg PCI-32765晶型A的晶种，加入320mL纯水制成悬浊液，并将体系温度控制到5℃左右。
3)将步骤1)中的PCI-32765游离碱的溶液在1小时左右匀速地滴加至步骤2)中的悬浊液中。滴加完毕后，在5℃维持1小时，然后在1小时内将结晶体系升温至40℃，熟化16小时后获得晶浆取样通过XRPD检测产品晶型，已完全转变为晶型A。
4)过滤步骤3)所得的晶浆，得到湿滤饼，用20mL纯水淋洗滤饼，然后在50℃的真空干燥箱中干燥滤饼约20小时至样品恒重。
该批次所得固体产品，称重，质量为9.5g，收率为94.9％，纯度为99.90％。经XRPD检测，即为PCI-32765的晶型A。
本实施例得到的晶型的X射线粉末衍射数据如表4所示。
表4
2theta d间隔 相对强度％
5.20 17.00 16.22
8.48 10.43 5.70
9.57 9.24 10.69
11.21 7.89 23.34
13.16 6.73 2.80
16.17 5.48 41.85
16.43 5.39 20.04
16.98 5.22 6.93
17.35 5.11 19.37
17.59 5.04 33.02
18.05 4.92 40.14
18.83 4.71 40.51
19.24 4.61 76.19
20.77 4.28 35.60
22.05 4.03 100.00
22.42 3.97 26.77
22.96 3.87 46.03
23.86 3.73 12.36
24.50 3.63 3.71
25.01 3.56 12.77
25.87 3.44 14.74
26.37 3.38 2.68
27.85 3.20 6.13
28.90 3.09 9.63
29.42 3.04 1.71
实施例5
PCI-32765晶型A的制备方法：按下述方法生产两批次的PCI-32765晶型A。
1)称取1.03g PCI-32765游离碱固体，在室温条件下加入10mL体积比为1∶1的甲醇/二甲亚砜混合溶剂，预过滤后将澄清溶液在25～40℃条件下密封保存待用。
2)称取100mg PCI-32765晶型A的晶种，加入30mL纯水制成悬浊液，并将体系温度控制到0℃左右。
3)将步骤1)中的PCI-32765游离碱的溶液在10分钟左右匀速地滴加至步骤2)中的悬浊液中。滴加完毕后，在0℃维持20小时获得晶浆，取样通过XRPD检测产品晶型，已完全转变为晶型A。
4)过滤步骤3)所得的晶浆，得到湿滤饼，用2mL纯水淋洗滤饼，然后在45℃的真空干燥箱中干燥滤饼约20小时至样品恒重。
上述第一批次，规模为1g，所得固体产品，称重，质量为0.89g，收率为 79.0％，纯度为100.0％。经XRPD检测，即为PCI-32765的晶型A。
第二批次工艺方法同第一批次，规模为0.3g，所得固体产品，称重，质量为0.27g，收率为80.0％，纯度为100.0％。产品经XRPD检测，即为PCI-32765的晶型A。
本实施例得到的晶型的X射线粉末衍射数据如表5所示。
表5
2theta d间隔 相对强度％
5.20 17.00 36.43
11.22 7.89 12.08
16.19 5.48 33.84
16.41 5.40 23.53
17.37 5.11 19.71
17.63 5.03 22.57
18.08 4.91 33.43
18.87 4.70 30.72
19.29 4.60 63.34
20.84 4.26 25.71
22.08 4.03 100.00
22.45 3.96 23.36
23.03 3.86 41.70
23.90 3.72 11.90
25.12 3.54 10.19
对比例1
称取5.0g PCI-32765游离碱固体粉末，加入150mL异丙醇和正庚烷体积比为2∶3的混合溶剂中，室温下搅拌12h，尚未形成澄清溶液。
对比例2
称取491mg PCI-32765游离碱固体粉末，加入16mL异丙醇和正庚烷体积比为1∶5的混合溶剂中，50℃下搅拌12h，尚未形成澄清溶液。
对比例3
称取102.4mg PCI-32765游离碱固体粉末，室温溶解于4mL丙酮中，将该溶液预过滤，向其中缓慢加入16mL正庚烷，搅拌过夜，得到的产品经X射线粉末衍射检测为原研专利WO2013184572A1中报道的晶型A。
本对比例得到的产品的X射线粉末衍射图谱如图4所示。

Claims (17)

  1. 一种PCI-32765晶型A的制备方法，其特征在于：包括以下步骤：
    1)PCI-32765游离碱溶液的配制：将PCI-32765的游离碱固体溶解于正溶剂中；
    2)将步骤1)中的溶液滴加到反溶剂中，滴加完毕后在0～20℃的温度条件下搅拌，并加入PCI-32765晶型A的晶种，或将步骤1)中的溶液在0～20℃的温度条件下滴加到含PCI-32765晶型A晶种的悬浊液中；
    3)控制步骤2)所得的溶液体系持续搅拌熟化至转晶完全，获得晶浆；
    4)步骤3)中所述晶浆，经过滤，洗涤，干燥后，得到PCI-32765晶型A的粉末。
  2. 根据权利要求1所述的制备方法，其特征在于：所述正溶剂为甲醇或含甲醇的混合溶剂。
  3. 根据权利要求2所述的制备方法，其特征在于：所述的混合溶剂为体积比为1∶0.8～1.2的甲醇和二甲亚砜。
  4. 根据权利要求1所述的制备方法，其特征在于：步骤1)中，在10～50℃下配制所述的PCI-32765游离碱溶液。
  5. 根据权利要求1所述的制备方法，其特征在于：所述反溶剂为纯水。
  6. 根据权利要求1所述的制备方法，其特征在于：步骤2)中所述的PCI-32765晶型A的晶种的投料质量与步骤1)中所述的PCI-32765游离碱投料质量比为0.01～0.1∶1。
  7. 根据权利要求1至3中任一项所述的制备方法，其特征在于：步骤1)中，所述的正溶剂的投料体积与所述的PCI-32765游离碱的投料质量比为10～40mL/g。
  8. 根据权利要求1或5所述的制备方法，其特征在于：步骤2)中所述的反溶剂的投料体积与步骤1)中所述的PCI-32765游离碱的投料质量比为30～80mL/g。
  9. 根据权利要求1所述的制备方法，其特征在于：步骤2)中，所述的步骤1)中的溶液滴加到所述的反溶剂或所述的悬浊液中的速度为1～30mL/min。
  10. 根据权利要求1所述的制备方法，其特征在于：步骤2)中所述的温度条件为0～10℃。
  11. 根据权利要求10所述的制备方法，其特征在于：步骤2)中所述的温度条件为0～5℃。
  12. 根据权利要求1所述的制备方法，其特征在于：步骤3)中所述的熟化的温度为0～40℃。
  13. 根据权利要求12所述的制备方法，其特征在于：步骤3)中所述的熟化的温度为0～30℃。
  14. 根据权利要求13所述的制备方法，其特征在于：步骤3)中所述的熟化的温度为0～20℃。
  15. 根据权利要求1所述的制备方法，其特征在于：步骤3)的具体方法为：控制步骤2)所得的溶液体系持续搅拌，然后在0～5℃下恒温熟化15～24小时；或者，将步骤2)所得的溶液体系在0～5℃维持1～3小时，然后升温至10～20℃，在10～20℃下维持10～15小时，获得晶浆。
  16. 根据权利要求1所述的制备方法，其特征在于：步骤4)中所用的洗涤溶剂为纯水。
  17. 根据权利要求1所述的制备方法，其特征在于：步骤4)中的干燥条件的控制如下：将洗涤过的样品放置于30～50℃的真空干燥箱中干燥至样品恒重。
PCT/CN2016/076779 2015-03-20 2016-03-18 一种pci-32765晶型a的制备方法 WO2016150349A1 (zh)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2016236578A AU2016236578B2 (en) 2015-03-20 2016-03-18 Preparation method of crystalline form a of pci-32765
CA2980418A CA2980418C (en) 2015-03-20 2016-03-18 Preparation method of crystalline form a of pci-32765
JP2017567523A JP6657269B2 (ja) 2015-03-20 2016-03-18 Ｐｃｉ―３２７６５の結晶型ａの調製方法
EP16767726.9A EP3272753B1 (en) 2015-03-20 2016-03-18 Preparation method of pci-32765 crystal form a
MX2017011990A MX2017011990A (es) 2015-03-20 2016-03-18 Metodo de preparacion de la forma a cristalina de pci-32765.
US15/559,777 US10138239B2 (en) 2015-03-20 2016-03-18 Preparation method of crystalline form a of PCI-32765
IL254530A IL254530A0 (en) 2015-03-20 2017-09-17 Preparation method of crystalline form a of pci-32765

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510126412 2015-03-20
CN201510126412.4 2015-03-20

Publications (1)

Publication Number Publication Date
WO2016150349A1 true WO2016150349A1 (zh) 2016-09-29

Family

ID=56310982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/076779 WO2016150349A1 (zh) 2015-03-20 2016-03-18 一种pci-32765晶型a的制备方法

Country Status (9)

Country Link
US (1) US10138239B2 (zh)
EP (1) EP3272753B1 (zh)
JP (1) JP6657269B2 (zh)
CN (1) CN105669679A (zh)
AU (1) AU2016236578B2 (zh)
CA (1) CA2980418C (zh)
IL (1) IL254530A0 (zh)
MX (1) MX2017011990A (zh)
WO (1) WO2016150349A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
EP3501609A1 (en) 2017-12-08 2019-06-26 Zentiva K.S. Pharmaceutical compositions comprising ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831788B (zh) * 2017-01-22 2020-10-30 鲁南制药集团股份有限公司 伊布替尼精制方法
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company NEW FORMS OF IBRUTINIB
CN115639091B (zh) * 2022-12-21 2023-03-17 南通嘉鹏新材料科技有限公司 一种聚酯热熔胶的硬度检测设备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
CN104327085A (zh) * 2013-11-27 2015-02-04 苏州晶云药物科技有限公司 Pci-32765的晶型a及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702548A (en) * 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
EP2914296B2 (en) * 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
CN104327085A (zh) * 2013-11-27 2015-02-04 苏州晶云药物科技有限公司 Pci-32765的晶型a及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3272753A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
EP3501609A1 (en) 2017-12-08 2019-06-26 Zentiva K.S. Pharmaceutical compositions comprising ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib

Also Published As

Publication number Publication date
EP3272753B1 (en) 2020-03-04
EP3272753A4 (en) 2018-07-25
AU2016236578B2 (en) 2019-04-04
CN105669679A (zh) 2016-06-15
US20180065958A1 (en) 2018-03-08
IL254530A0 (en) 2017-11-30
US10138239B2 (en) 2018-11-27
JP6657269B2 (ja) 2020-03-04
JP2018508584A (ja) 2018-03-29
CA2980418A1 (en) 2016-09-29
EP3272753A1 (en) 2018-01-24
CA2980418C (en) 2019-07-09
MX2017011990A (es) 2018-06-06
AU2016236578A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
WO2016150349A1 (zh) 一种pci-32765晶型a的制备方法
JP6691218B2 (ja) 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
EP3337485B1 (en) Crystalline forms of ibrutinib
TWI706951B (zh) 一種週期素依賴性蛋白激酶抑制劑的羥乙基磺酸鹽、其結晶形式及製備方法
JP7168447B2 (ja) ビラスチンの結晶形態及びそれらの調製方法
CN103193864B (zh) 培哚普利的精氨酸盐的δ晶型、其制备方法和包含它的药物组合物
WO2016127844A1 (zh) IPI-145的晶型α及其制备方法
AU2015206758B2 (en) Solid forms of tenofovir
WO2023193440A1 (zh) 一种卢比替定的晶型及其制备方法
CN107531744A (zh) 一种奥贝胆酸的新结晶形式及其制备方法
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
WO2017177781A1 (zh) Ahu377的晶型及其制备方法与用途
JP6761564B2 (ja) ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
WO2016157136A1 (en) Crystalline forms of idelalisib
CN116496247A (zh) 6-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)尼克酰胺的晶型
EP3004104A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
CZ2016275A3 (cs) Krystalická forma Enzalutamidu
TW202227387A (zh) 單水合曲前列環素晶體及其製備方法
KR102657147B1 (ko) 빌라스틴의 결정형 및 그의 제조 방법
TWI592397B (zh) 卡維地洛硫酸鹽的結晶、其製備方法及其在醫藥上的應用
WO2017032281A1 (zh) 帕比司他乳酸盐的新晶型
WO2019001325A1 (zh) 雷西纳得的晶型xv及其制备方法
CN111303156A (zh) 一种依布替尼新晶型及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16767726

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 254530

Country of ref document: IL

REEP Request for entry into the european phase

Ref document number: 2016767726

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/011990

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 15559777

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2980418

Country of ref document: CA

Ref document number: 2017567523

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016236578

Country of ref document: AU

Date of ref document: 20160318

Kind code of ref document: A